Fluticasone furoate (FF)/vilanterol (100/25 mcg or 200/25 mcg) or FF (100 mcg) in persistent asthma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Fluticasone furoate (FF)/vilanterol (100/25 mcg or 200/25 mcg) or FF (100 mcg) in persistent asthma

Published:2015-08-18 Issue:10 Volume:52 Page:1073-1083
ISSN:0277-0903
Container-title:Journal of Asthma
language:en
Short-container-title:Journal of Asthma

Author:

Bernstein David I.,Bateman Eric D.,Woodcock Ashley,Toler William T.,Forth Richard,Jacques Loretta,Nunn Carol,O'Byrne Paul M.

Publisher

Informa UK Limited

Subject

Pulmonary and Respiratory Medicine,Immunology and Allergy,Pediatrics, Perinatology, and Child Health

Link

http://www.tandfonline.com/doi/pdf/10.1080/10256018808623883

Reference28 articles.

1. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids.

2. Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma

3. Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma

4. Efficacy and optimal dosing interval of the long-acting beta2 agonist, vilanterol, in persistent asthma: A randomised trial

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Baseline Characteristics and Maintenance Therapy Choice on Symptom Control, Reliever Use, Exacerbation Risk in Moderate–Severe Asthma: A Clinical Modelling and Simulation Study;Advances in Therapy;2024-09-06

2. The evidence base for ICS/formoterol maintenance and reliever therapy in severe asthma;European Respiratory Journal;2024-06

3. Once-daily fluticasone furoate/vilanterol vs once-daily fluticasone furoate in patients with asthma aged 5 to 17 years;Annals of Allergy, Asthma & Immunology;2024-06

4. Asthma management with triple ICS/LABA/LAMA combination to reduce the risk of exacerbation: an umbrella review compliant with the PRIOR statement;Expert Opinion on Pharmacotherapy;2024-05-23

5. Development and validation of a claims-based algorithm to identify moderate exacerbations in patients with asthma treated in the US;Respiratory Medicine;2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3